BridgeBio Pharma, Inc. recently announced a US$550,000,000 fixed-rate senior subordinated unsecured notes offering under Rule 144A, while updating investors on advancing late-stage programs and ...
BridgeBio Pharma, Inc. has announced the pricing of $500 million in convertible senior notes at a 1.75% interest rate, maturing in 2031, in a private offering aimed at qualified institutional buyers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results